Please use this identifier to cite or link to this item:
|dc.title||Retinal venular caliber predicts visual outcome after intravitreal ranibizumab injection treatments for neovascular AMD|
|dc.identifier.citation||Wickremasinghe, S.S., Busija, L., Guymer, R.H., Wong, T.Y., Qureshi, S. (2012-01). Retinal venular caliber predicts visual outcome after intravitreal ranibizumab injection treatments for neovascular AMD. Investigative Ophthalmology and Visual Science 53 (1) : 37-41. ScholarBank@NUS Repository. https://doi.org/10.1167/iovs.11-7689|
|dc.description.abstract||PURPOSE. To examine whether baseline retinal vascular caliber predicts visual response to intravitreal ranibizumab injections in patients with neovascular age-related macular degeneration (AMD). METHODS. In this prospective cohort study, patients with neovascular AMD received three monthly intravitreal injections of ranibizumab, followed by as needed dosing up to 1 year. Retinal vascular caliber was measured from digital fundus photographs at baseline and summarized as central retinal artery equivalent (CRAE) and venular equivalent (CRVE), representing average caliber of arterioles and venules, respectively. Visual outcome at 12 months was assessed and the relation to baseline retinal vascular caliber was determined. RESULTS. A total of 88 eyes were analyzed at baseline. After accounting for age, sex, size of choroidal neovascularization, and number of injections, patients who deteriorated in visual acuity at 12 months had significantly larger baseline CRVE, 243.10 μm (95% confidence interval [CI], 227.01-259.19), compared with those who were stable, 214.30 μm (95% CI, 205.79-222.81) and those who improved, 215.26 μm (95% CI, 204.69-225.84; P = 0.007). Baseline CRAE did not differ significantly from eyes whose vision deteriorated, 150.12 μm (95% CI, 140.67-159.57), compared with those remaining stable, 143.64 μm (95% CI, 138.64-148.63), or gaining vision 142.92 μm (95% CI, 136.71-149.13; P = 0.69). CONCLUSIONS. In eyes with neovascular AMD treated with intravitreal ranibizumab, larger baseline retinal venular caliber was significantly associated with a poorer response to treatment, possibly reflecting increased disease severity. © 2012 The Association for Research in Vision and Ophthalmology, Inc.|
|dc.description.sourcetitle||Investigative Ophthalmology and Visual Science|
|Appears in Collections:||Staff Publications|
Show simple item record
Files in This Item:
There are no files associated with this item.
checked on Oct 19, 2021
WEB OF SCIENCETM
checked on Oct 19, 2021
checked on Oct 14, 2021
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.